Our Promise to you:
Premier global microbiological solutions, extensive collection of products.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Liver cancer, mostly hepatocellular carcinoma (HCC), is a relatively rare form of cancer that has a high mortality rate. The development of personalized molecular targeted therapies for HCC has been ongoing for many years. Targeted therapies act on specific genes, proteins, or the tissue environment that contributes to the growth and spread of cancer.
Fig.1 Signal transduction in solid cancer cells including hepatocellular carcinoma.
For some types of cancer, molecular targeted therapies may act on better than other treatments. Targeted therapy drugs which are generally available for Liver cancer are listed below.
|Target||Types||Agent||Manufacturer||Start Marketing Date|
|VEGFR1, VEGFR2, VEGFR3, PDGFR-β, Kit, RET, Raf-1||Small molecule||Stivarga||Bayer||2012|
|VEGFR-1, VEGFR-2, VEGFR-3, FGFR1, PDGFR, cKit, Ret, PD-1||Small molecule||Lenvima||Esai||2015|
|KIT, VEGFR, PDGFR||Small molecule||Nexavar||Bayer||2005|
In the field of cancer treatment, it was observed that the bacteria have the ability to deliver tumor-specific anticancer genes and the potential tumor-targeting antitumor capability. Creative Biogene is specializing in providing Complete Solutions for oncolytic bacteria genome editing to help you every step of the way in your genome editing workflow.
• non-toxic to the host
• selective for a specific type of tumor
• harmless to normal tissue
• manipulated easily
• Bacterial Gene Knockout Service
• Bacterial Gene Knockin/replacement Service
• Bacterial Gene Site-directed Mutagenesis Service
1. Kudo, M. (2012). Targeted Therapy for Liver Cancer: Updated Review in 2012. Current Cancer Drug Targets, 12(9), 1062–1072.